Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epirubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.92 |
| ▸ | MEN1 | O00255 | 8/20 | 0.92 |
| ▸ | THRB | P10828 | 8/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.92 |
| ▸ | RECQL | P46063 | 7/20 | 0.92 |
| ▸ | BLM | P54132 | 7/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.92 |
| ▸ | BRCA1 | P38398 | 7/20 | 0.92 |
| ▸ | MAPT | P10636 | 6/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.92 |
| ▸ | STAT6 | P42226 | 5/20 | 0.92 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.92 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.92 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.92 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.92 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.92 |
| ▸ | PGR | P06401 | 3/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxorubicin SCHEMBL28183637 | 1.00 | MEN1 (0.92) | MEN1THRBKMT2ARECQLBLM | |
| Doxorubicin SCHEMBL13858183 | 1.00 | MEN1 (0.92) | MEN1THRBKMT2ARECQLBLM | |
| Epirubicin SCHEMBL8183120 | 0.99 | MEN1 (0.92) | MEN1THRBKMT2ARECQLBLM | |
| Epirubicin SCHEMBL1030848 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ARECQLBLM | |
| Epirubicin SCHEMBL18263941 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ARECQLBLM | |
| Doxorubicin SCHEMBL147967 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ARECQLBLM | |
| Doxorubicin SCHEMBL23753547 | 0.98 | MEN1 (0.95) | MEN1THRBKMT2ARECQLBLM | |
| Doxorubicin SCHEMBL28086230 | 0.98 | MEN1 (0.95) | MEN1THRBKMT2ARECQLBLM | |
| Doxorubicin SCHEMBL4019285 | 0.98 | MEN1 (0.95) | MEN1THRBKMT2ARECQLBLM | |
| Esorubicin SCHEMBL17968332 | 0.96 | MEN1 (0.85) | MEN1THRBKMT2ARECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040104-B2 | Radiopaque polymers | BIOCOMPATIBLES UK LTD. (GB) | 2021-06-22 | — | — | US | claimed |
| US-20130209578-A1 | Combinatory Cancer Treatment | UNIVERSITE DE MONTREAL (CA) | 2013-08-15 | — | — | US | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| EP-1140022-B8 | METHOD OF ADMINISTERING A COMPOUND TO MULTI-DRUG RESISTANT CELLS | HADASIT MED RES SERVICE (IL) | 2008-10-15 | — | — | EP | claimed |
| US-20060062842-A1 | Method of administering a compound to multi-drug resistant cells | ALZA CORPORATION | 2006-03-23 | — | — | US | claimed |
| US-20040161457-A1 | Method of administering a compound to multi-drug resistant cells | ALZA CORPORATION | 2004-08-19 | — | — | US | claimed |
| EP-1140022-A2 | METHOD OF ADMINISTERING A COMPOUND TO MULTI-DRUG RESISTANT CELLS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT COMPANY, LTD. (IL) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035422-A2 | METHOD OF ADMINISTERING A COMPOUND TO MULTI-DRUG RESISTANT CELLS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (IL) | 2000-06-22 | — | — | WO | claimed |
| WO-2024115919-A1 | MODIFIED T CELLS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-06-06 | — | — | WO | disclosed |
| US-20240150482-A1 | BISPECIFIC POLYPEPTIDES FOR ENGAGEMENT OF CAR EXPRESSING IMMUNE CELLS WITH ANTIGEN PRESENTING CELLS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2024-05-09 | — | — | US | disclosed |
| WO-2024089683-A1 | ANTICANCER DRUG CONJUGATES | Ariel Scientific Innovations Ltd. (IL) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024079433-A1 | PMHC-BINDING HETERODIMERIC RECEPTORS WITH AN IMPROVED DISCRIMINATION BETWEEN A LOW AFFINITY AND A HIGH AFFINITY PMHC AND THAT DO NOT ASSOCIATED WITH CD3 | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024059901-A1 | A METHOD OF RESCUING EXHAUSTED IMMUNE CELLS | Currus Biologics Pty Ltd (AU) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024059899-A1 | BISPECIFIC POLYPEPTIDES AND USES THEREOF | Currus Biologics Pty Ltd (AU) | 2024-03-28 | — | — | WO | disclosed |
| CN-1938046-A | Monomethylvaline compounds capable of coupling to ligands | SEATTLE GENETICS INC (US) | 2007-03-28 | — | — | CN | disclosed |
| EP-1708700-A1 | METAL SALTS OF PARECOXIB AS PRODRUGS OF THE COX-2 INHIBITOR VALDECOXIB FOR THE TREATMENT OF INFLAMMATION, PAIN AND/OR FEVER | Pharmacia Corporation (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005065684-A1 | METAL SALTS OF PARECOXIB AS PRODRUGS OF THE COX-2 INHIBITOR VALDECOXIB FOR THE TREATMENT OF INFLAMMATION, PAIN AND/OR FEVER | PHARMACIA CORPORATION (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-1998001136-A9 | FORMULATIONS OF VESICANT DRUGS AND METHODS OF USE THEREOF | — | 1998-04-23 | — | — | WO | disclosed |
| WO-1998001136-A1 | FORMULATIONS OF VESICANT DRUGS AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 1998-01-15 | — | — | WO | disclosed |
| WO-1997039007-A1 | COMPOUNDS AND METHODS FOR THE SELECTIVE TREATMENT OF CANCER AND BACTERIAL INFECTIONS | PRO-NEURON, INC. (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130209578-A1 | Combinatory Cancer Treatment | EIF4EBP1, RNMT, EIF4E | TOP2A 1307/4885MEN1 2969/4885THRB 2026/4885 |
| US-11040104-B2 | Radiopaque polymers | RXFP3, RXFP1, DAGLA | TOP2A 1024/4885MEN1 452/4885THRB 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.